诺和诺德CEO:公司需付出更多努力赢得投资者信任

格隆汇
Sep 22
诺和诺德CEO迈克·杜斯特达尔表示,鉴于公司旗下主力药物(如Ozempic)将在未来十年初面临专利到期挑战,公司必须采取更多措施来建立投资者信心。杜斯特达尔表示:“过去几年我们学到的是,过度承诺和交付不足会很快失去信任。”投资者“想知道接下来会发生什么”。诺和诺德股价周一下跌,因该公司的资本市场日让投资者对其扭亏计划缺乏细节感到失望。诺和诺德正面临Ozempic和Wegovy在美国和欧洲的专利到期,这一产品系列目前贡献约四分之三的销售额。诺和诺德承诺到2030年推出超过五款重磅新药,到2035年实现超过230亿美元的新增销售额。这些目标被广泛认为已符合投资者预期。BMO资本市场分析师表示,诺和诺德仍处于需用实绩证明自己的阶段。投资者需要更清晰地了解该公司的下一代药物及其潜在的市场接纳度,以便重建信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10